Citius (CTXR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

$1.5M

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$11.9M

Net income growth (year over year)

−29.50%

Net margin

—

Return on equity

−70.29%

EPS (trailing twelve months)

−$1.75

Book value per share

$2.43

P/E (trailing twelve months)

—

Price to book

0.17

Debt to assets

46.64%

Payout ratio

—

Dividend yield

—

Company profile

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

• How do I buy stock in Citius (CTXR)?

  CTXR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.